Related Experiment Video
Updated: Jun 14, 2026
09:19
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo
Published on: February 6, 2015
Drug development in oncology: a regulatory perspective
1F. Hoffmann-La Roche, Basel, Switzerland. stella.augustus@roche.com
American Journal of Therapeutics
|March 26, 2010
Summary
Drug development in oncology faces challenges in demonstrating efficacy to regulators. Harmonized expectations and pragmatic decision-making are crucial for efficient oncology drug approval.
Area of Science:
- Oncology
- Drug Development
- Regulatory Science
Background:
- Drug development in oncology aims for regulatory approval, but demonstrating efficacy presents significant challenges.
- Key factors influencing success include clinical trial design, endpoint selection, and comparator choice.
Purpose of the Study:
- To highlight critical aspects of oncology drug development that impact regulatory approval.
- To emphasize the need for harmonized regulatory expectations and pragmatic decision-making.
Main Methods:
- Review of key considerations in oncology clinical trial design, conduct, and analysis.
- Analysis of the impact of endpoint selection and comparator choice on drug registrability.
Main Results:
- The choice of primary/secondary endpoints and comparators critically affects medicine registrability and trial feasibility.
- Independent radiologic review of endpoints like progression-free survival and tumor response is essential.
Conclusions:
- Greater collaboration and dialogue between industry and regulatory authorities can enhance clarity and efficiency.
- Harmonized expectations for 'proof of efficacy' are needed to streamline the path of new oncology medicines from clinical trials to patient care.
More Related Videos
Related Concept Videos
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:25Drug Regulation
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
01:28Preclinical Development: Overview
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
01:26Drug Administration and Therapy Phases: Overview
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
01:03Drug Control Governance: Regulatory Bodies and Their Impact
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with a...